SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · Two BridgeBio directors executed open-market sales totaling $11.56M on…

BridgeBio Pharma, Inc. · CLUSTER filed Jul 13, 2026 at 16:41 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed Jul 13, 2026 at 16:41 ET

Two BridgeBio directors executed open-market sales totaling $11.56M on July 9, 2026, following derivative exercises. Director Cook sold $10.12M at $90/share and Director Ellis sold $1.44M at $84/share. The sales represent ~0.07% of the $16.3B market cap, falling below the 0.1% materiality threshold, and are consistent with routine post-exercise diversification. No C-suite executives participated, and the cluster is not amplified by any cross-filing context that would suggest informed selling.

  • Two directors (Cook and Ellis) sold a combined $11.56M in open-market transactions on July 9, 2026
  • Director Cook sold 112,422 shares at $90/share ($10.12M) and 36,167 shares at $84/share ($3.04M)
  • Director Ellis sold 17,167 shares at $84/share ($1.44M)
  • All sales followed derivative exercises at prices between $0 and $29/share, generating non-cash gains

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access